RXi Pharmaceuticals this week announced that the US Food and Drug Administration has approved the company's investigational new drug application to begin human testing of an RNAi-based drug for scar reduction.

The drug, called RXI-109, uses RXi's so-called self-delivering RNAi technology to inhibit connective tissue growth factor, a protein linked to wound healing and other fibrotic processes. It will be tested in a phase I trial in surgical patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.

US lawmakers are considering eliminating the medical devices tax that is part of the Affordable Care Act.

Two research teams in China home in on a gene that gives rice a long, slender shape.

Marcia McNutt, the editor-in-chief of Science, has been nominated to become president of the US National Academy of Sciences.